Loading stock data…
Quanterix Corporation (QTRX)
$2.73+0.04 (+1.49%)
Market ClosedLast close Sep 8
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quanterix Corporation in the Healthcare sector is trading at $2.73 with a market capitalization of $145M. Wall Street consensus targets $3.00 (3 analysts), implying a +9.9% move over the next 12 months. The stock is currently near its 52-week low of $2.15, remaining 40.8% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 20/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +9.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $36.41M↓ | $43.78M↑ | $40.15M↑ | $24.45M↓ | $30.33M |
| Gross Profit | $15.57M↓ | $19.96M↑ | $17.12M↑ | $11.28M↓ | $14.84M |
| Operating Income | -$21.53M↑ | -$23.87M↑ | -$30.15M↓ | -$29.43M↓ | -$26.37M |
| Net Income | -$17.54M↑ | -$23.12M↑ | -$33.52M↓ | -$30.01M↓ | -$20.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Si...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$145.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.93%
Volume
Today's trading volume
646,892
Recent News
Quanterix (QTRX) Q2 2026 Earnings Call Transcript
Revenue guidance slashed as commercial execution stumbles and academic spending weakens.
Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test
Quanterix (NASDAQ:QTRX) CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma marke
Quanterix (QTRX) Earnings Shake Up The Story As Fair Value Still Sits Higher
Quanterix (QTRX) is back in focus after its 10 August second quarter report, which paired higher revenue with a wider net loss, a lower full year 2026 revenue outlook, and a new Chief Commercial Officer. See our latest analysis for Quanterix. Quanterix’s share price has been under pressure for some time, with the year to date share price return down 59.18% and the 1 year total shareholder return down 44.85%. The stock briefly rebounded with an 8.47% 1 day share price gain after the 10 August...
Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ...
Quanterix Corp (QTRX) lowers full-year 2026 revenue guidance to $142-$148 million as it navigates broad-based market headwinds and pushes cash flow break-even to 2027.
Quanterix Cuts 2026 Revenue Outlook as Commercial Challenges Delay Cash-Flow Break-Even
Quanterix reported 34% second-quarter revenue growth and lower adjusted cash usage, but weaker-than-expected commercial performance prompted a substantial guidance reduction and pushed expected cash-flow break-even into 2027. Key Investor TakeawaysQuanterix (NASDAQ:QTRX) reported Q2 2026 revenue of $32.